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Abstract
Background: Acute ischaemic stroke is associated with alteration in systemic markers of vascular function. We
measured forearm vascular function (using forearm flow mediated dilatation) to clarify whether recent acute
ischaemic stroke/TIA is associated with impaired systemic vascular function.
Methods: Prospective case control study enrolling 17 patients with recent acute ischaemic stroke/TIA and 17 sex
matched controls with stroke more than two years previously. Forearm vascular function was measured using flow
medicated dilatation (FMD).
Results: Flow mediated dilatation was 6.0 ± 1.1% in acute stroke/TIA patients and 4.7 ± 1.0% among control
subjects (p = 0.18). The mean paired difference in FMD between subjects with recent acute stroke and controls
was 1.25% (95% CI -0.65, 3.14; p = 0.18). Endothelium independent dilatation was measured in six pairs of
participants and was similar in acute stroke/TIA patients (22.6 ± 4.3%) and control subjects (19.1 ± 2.6%; p = 0.43).
Conclusions: Despite the small size of this study, these data indicate that recent acute stroke is not necessarily
associated with a clinically important reduction in FMD.
Introduction
Endothelial dysfunction, as measured by impaired bra-
chial flow-mediated dilatation, occurs early in athero-
sclerosis. It is associated with subsequent intracranial
small vessel disease (as manifest by small, deep, lacunar
ischaemic stroke and brain imaging evidence of deep
white matter infarction), and is an independent predic-
tor of vascular events[1-4]. Moreover, endothelial dys-
function can be reversed with treatments that lower
C-reactive protein and homocysteine, suggesting that
systemic inflammation may mediate the observed vascu-
lar dysfunction in patients with stable cerebrovascular
disease[5].
However, the importance of endothelial dysfunction in
the pathogenesis of acute ischaemic stroke and transient
ischaemic attacks (TIA) remains uncertain. Acute
ischaemic stroke is associated with a rise in markers of
endothelial activation in the systemic circulation [6,7]
and with fewer circulating endothelial progenitor cells
[8] but whether these results reflect an underlying pri-
mary disturbance of endothelial function in the patho-
genesis of acute ischaemic stroke, or an acute phase
response to the cerebral injury, is unknown. The
endothelial marker E-selectin is elevated in acute stroke
and returns to normal concentrations within 3-6
months[6]. However it is not known if endothelial func-
tion is impaired in subjects with acute stroke (compared
to those who have suffered a remote stroke).
We hypothesised that acute ischaemic stroke would be
associated with impairment of systemic endothelial dys-
function. Our aim was to measure systemic vascular
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function directly (using forearm flow mediated dilata-
tion) in patients with acute ischaemic stroke, and con-
trols with stable cerebrovascular disease, to clarify
whether recent acute ischaemic stroke/TIA is in fact
associated with impaired systemic vascular function.
Materials and methods
Ethics
The research was approved by the Royal Perth Hospital
Ethics Committee. All participants provided written
consent.
Design
Prospective case-control study.
Setting
Acute stroke units and TIA clinics of two university
teaching hospitals in Perth, Australia.
Subjects
Cases of recent acute TIA or ischaemic stroke
Inclusion criteria
Patients with a clinical diagnosis of acute ischaemic
stroke or TIA within the previous 10 days. All partici-
pants underwent brain imaging with computed tomo-
graphy. Clinical records were reviewed subsequent to
the patient’s discharge to confirm a final clinical diagno-
sis of an acute cerebral ischaemic event and classify the
clinical syndrome using the Oxfordshire Community
Stroke Project classification [9].
Exclusion criteria
Patients with blood glucose level >13 mmol/L and those
with diagnosed infection or malignancy.
Controls
Control participants were patients who had a history of
acute ischaemic stroke or TIA more than two years pre-
viously, had been enrolled in the VITamins TO Prevent
Stroke Trial,[10] taken part in a completed sub-study of
arterial inflammation,[11] and were placebo treated. Sex
matched control subjects closest to the age of cases with
acute stroke/TIA patients were selected. This resulted in
sex matched controls with mean age difference of ± 1.1
years (maximum ± 7 years) from recent acute stroke/
TIA subjects at the time of assessment of forearm flow
mediated dilatation.
Baseline measures
Baseline variables, measured upon presentation to hospi-
tal at the time of the qualifying cerebrovascular event,
for both cases and controls included demographic and
clinical features, and are shown in table 1. Table 1 also
shows age of the cases and control participants at the
time of assessment of forearm flow mediated dilatation.
Outcome Measures
The primary outcome was forearm flow mediated dilata-
tion (FMD). FMD was measured by a single operator
using a semi-automated custom-designed edge-detection
and wall-tracking software designed to reduce investiga-
tor bias, as described previously [12]. Video files are
provided demonstrating set-up (Additional File 1) and
acquisition of images (Additional File 2). Briefly, partici-
pants lay supine on a flat examination couch in a quiet
laboratory and B-mode ultrasound images were
recorded using a 10 MHz multi-frequency linear array
probe attached to a high-resolution ultrasound (Acuson
Aspen, Mountain View, California). FMD was measured
in the left arm except in subjects with a left hemiplegia.
B-mode images of the brachial artery were obtained and
recorded continuously for one minute to assess baseline
arterial diameter. A rapid inflation/deflation pneumatic
cuff placed around the forearm was inflated to 250
mmHg for five minutes. Post cuff deflation images were
recorded continuously for two minutes to capture peak
arterial dilation. Glyceryl trinitrate (GTN) mediated dila-
tation was also measured for the first six participants.
Table 1 Clinical variables
Recent Stroke/TIA n
= 17
Stable Disease n
= 17
p
Gender, n = F 6 (35%) 6 (35%)
Age at FMD scan,
years
64.2 ± 13.0 64.7 ± 11.7 0.23
Medical History
Myocardial Infarction 2 (12%) 1 (6%) 1.0
Hypertension 15 (89%) 15 (89%) 1.0
Hypercholesterolaemia 11 (65%) 12 (71%) 0.71
Diabetes 2 (12%) 3 (18%) 1.0
Smoking 9 (53%) 9 (53%) 1.0
Prior Therapy
Antihypertensive 12 (71%) 14 (83%) 0.6
Lipid Lowering 12 (71%) 11 (65%) 0.72
Clinical Variables
Clinical Syndrome
TACS
1 (6%) 2 (12%)
PACS 6 (35%) 4 (24%)
LACS 4 (24%) 6 (35%)
POCS 2 (12%) 1 (6%)
TIA 4 (24%) 4 (24%)
SBP, mmHg 139.9 ± 21.0 138.9 ± 18.7 0.86
DBP, mm Hg 84.1 ± 13.6 79.6 ± 14.7 0.21
Cholesterol, mmolL-1 3.9 ± 0.9 4.2 ± 0.9 0.44
Triglycerides, 1.1 ± 0.3 1.3 ± 0.5 0.25
HDL, mmolL-1 2.1 ± 1.1 2.2 ± 0.6 0.77
LDL, mmolL-1 1.3 ± 0.5 1.4 ± 0.6 0.52
Data are N (%) or N ± SD; TACI = Total Anterior Circulation, PACI = Partial
Anterior Circulation, LACI = Lacunar, TIA = Transient Ischaemic attack; S(D)BP
= Systolic (Diastolic) Blood Pressure; H(L)DL = High (Low) Density Lipoprotein.
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In light of the high prevalence of multi-agent antihyper-
tensive therapy it was considered prudent to complete
data collection without exposing additional participants
to GTN (which can be associated with systemic hypo-
tension). FMD and GTN mediated dilation were mea-
sured off-line. The mean intra-observer coefficient of
variation for FMD and GTN-mediated dilation mea-
sured by this technique are 6.7% and 3.9% respectively
[12].
Statistical Analysis
Log-normal data were log transformed prior to analysis
and compared using paired t tests. Non-normal data
were analysed using non parametric tests. Categorical
variables were assessed with the chi squared or fisher
exact test. Data were analysed using SPSS 15.0
Results
Baseline measures
We recruited 17 patients with recent acute ischaemic
stroke (n = 16) or TIA (n = 1), and 17 age- and sex-
matched controls who had experienced an ischaemic
stroke or TIA more than two (median 4) years
previously.
Cases and controls were adequately matched, with no
significant differences between the two groups in the
variables evaluated. (Table 1) The presenting syndromes
of the cases with recent acute ischaemic stroke, and
control participants, were varied. Among the patients
with recent acute stroke or TIA, 1 had a total anterior
circulation syndrome, 6 had partial anterior circulation
syndromes, 4 had lacunar syndromes, 2 had posterior
circulation syndromes, and 4 had presented with a TIA.
Control subjects had a history of TIA (n = 4) or total
anterior (n = 2), partial anterior (n = 4), lacunar (n = 6)
or posterior (n = 1) syndrome ischaemic stroke.
Outcome measures
Table 2 shows that the baseline arterial diameter, flow
mediated dilatation and endothelium independent dila-
tation were similar in participants with recent acute
stroke/TIA and controls with stable cerebrovascular dis-
ease. The mean paired difference in FMD between
subjects with recent acute stroke and controls was
1.25% (95% CI -0.65, 3.14; p = 0.18).
Mean blood pressure after the administration of GTN
to 6 subjects with recent acute stroke/TIA was 144.4/
85.6 mmHg, which did not differ significantly from the
baseline mean systolic (152.2 mmHg; p = 0.34) or dia-
stolic (87.2 mmHg, p = 0.83) blood pressures among
this group. No adverse events related to the administra-
tion of GTN were observed.
Discussion
Principal findings
These data suggest that vascular function, measured
with FMD, is similar in patients with recent acute and
stable cerebrovascular disease. If anything, FMD tended
to be better in subjects with acute stroke, which was an
unexpected finding. These data do not support the
hypothesis that acute stroke is associated with worsen-
ing of systemic vascular function. The lower limit of the
95% confidence interval of the mean paired differences
between subjects with recent acute stroke and controls
with prior cerebrovascular disease was -0.65%. This
effectively excludes a worsening of FMD associated with
acute ischaemic stroke of a magnitude which would be
considered clinically important (>2%)[13].
Currently, concern regarding the safety of administra-
tion of GTN to people with acute ischaemic stroke pre-
cludes full measurement of FMD in acute stroke
patients outside research protocols. Our preliminary
data suggest that GTN mediated FMD can be safely
assessed in people with recent acute ischaemic stroke.
Further work in this population would ideally assess
flow and GTN mediated dilatation, to ensure any
observed differences are endothelium dependent (rather
than due to differences in smooth muscle function, for
example related to statin therapy). Safety of assessment
of FMD in the acute phase of stroke could be confirmed
by continuous BP monitoring whilst GTN is adminis-
tered, combined with assessment of cerebral perfusion.
Results in context of other studies
Our findings are consistent with other data suggesting
that endothelial function is not necessarily worse in sub-
jects with recent acute stroke compared to subjects with
Table 2 Forearm vascular function
Acute Stroke or TIA Mean ± SEM Stable Cerebrovascular Disease Mean ± SEM p
Endothelium dependent vasodilatation n = 17 n = 17
Baseline Diameter (mm) 3.6 ± 0.2 3.5 ± 0.2 0.53
FMD (%) 6.0 ± 1.1 4.7 ± 1.0 0.18
Endothelium independent vasodilatation n = 6 n = 6
GTN-mediated dilatation (%) 22.6 ± 4.3 19.1 ± 2.6 0.43
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stable disease. For example, individuals with sympto-
matic ICA stenosis and severe periventricular white
matter lesions had higher levels of VCAM-1 (a marker
of endothelial cell activation) than subjects with acute
stroke[14]. We are aware of only one other study that
has assessed FMD in patients with acute stroke[15].
Those data were collected to test the hypothesis that
endothelial dysfunction contributes to the risk of arterial
stroke to a greater extent than embolic stroke, and thus
did not utilize healthy or disease controls. Patients hos-
pitalised with ischaemic stroke and atrial fibrillation
within 5-10 days (n = 20) were found to have less
impaired vascular function (5.7 ± 3.3%) than patients
with ischaemic stroke in sinus rhythm (n = 32; 3.2 ±
2.4%; p = 0.041)[15]. Future work should stratify partici-
pants according to stroke sub-type. FMD has been
found to be associated with survival free from cardiac
events,[16] and composite cardiovascular outcomes[4].
Although our data suggest that FMD does not differ sig-
nificantly between patients with acute stroke and stable
cerebrovascular disease, future work should determine
whether the degree of impairment of FMD is associated
with future cerebrovascular events.
Strengths of our study
To our knowledge this is the first study comparing fore-
arm vascular function in people with recent acute
ischaemic stroke or TIA and controls with stable cere-
brovascular disease. Inclusion of a control population,
sharing similar risk factor and treatment profiles to the
cases with acute ischaemic stroke/TIA, is a strength of
the study. Our aim was to determine the association of
acute stroke with vascular function, and we thus chose
to control for background cerebrovascular disease and
treatments. However the study would have been furth-
ered strengthened by the simultaneous inclusion of a
healthy control population. Our methodology is also
likely to be reliable, as the measurements were made by
a single observer using semi-automated edge detection
software. Forearm flow mediated dilatation (FMD) is a
validated non invasive marker of systemic endothelial
function and a functional assay of endothelium-derived
nitric oxide.
Potential weaknesses
The major weakness of our study is the potential for ran-
dom error because of the small number of patients and
controls studied. Because of the small data set, the results
may be falsely negative. Further, there is potential for
selection bias as the cases and controls were selected
from hospital and clinical trial populations respectively.
Interpretation of our data is limited by the heterogenous
nature of the participants with acute stroke/TIA. It might
be expected, for example, that participants with lacunar
or embolic stroke are less likely to show evidence of vas-
cular dysfunction than participants with large artery
embolic stroke. Our participants were heavily pre-treated
which may influence the observed results, given that
commonly used medications, such as statins, may
improve vascular function and reduce the risk of stroke
[17,18]. We also enrolled patients up to 10 days after
symptom onset and thus may have failed to ascertain dif-
ferences in the very early phase of acute stroke. Future
work should enrol patients in the very early phase after
stroke (ideally within first 24 hours of ictus).
Conclusion
• Despite the small size of this study, these data indi-
cate that recent acute stroke may not necessarily be
associated with a clinically important reduction in
FMD.
• These data suggest that subjects with stroke more
than two years previously have similar vascular func-
tion to subjects with recent stroke. The clinical uti-
lity of assessment of FMD in subjects with recent
acute ischaemic stroke thus remains uncertain.
Additional material
Additional file 1: Set-up of semi-automated software for
measurement of flow mediated dilatation. A video file, demonstrating
preparation of the semi-automated system
Additional file 2: Acquisition of flow mediated dilatation data using
semi-automated software. A sample video file, demonstrating
acquisition of flow mediated dilatation data
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